Table 1.
Patients with advance CTCL and favorable short term clinical response on extra corporeal photopheresis momotherapgy
| Patient/age (years)/sex | DX | TNBM* | Months | Response | %SC | SC/mm3 | %CD4/8/7 | CD4/8 | CD4P7M/mm3† | LDH |
|---|---|---|---|---|---|---|---|---|---|---|
| 1/73/F‡ | SS | T4(2)NXB2 | 0 | 44 | 2760 | 87/3/59 | 29.0 | 2070 | 172 | |
| 3 | NC | 52 | 2944 | 76/4/54 | 19.0 | 1698 | 153 | |||
| 6 | MR | 58 | 2127 | 89/4/72 | 22.3 | 734 | 155 | |||
| >6 | IFN-α: NR | |||||||||
| 2/48/M‡ | ECTCL, NOS | T4N1B1 | 0 | 17 | 317 | 54/24/68 | 2.3 | – | 184 | |
| 3 | MR | 15 | 288 | 48/18/63 | 2.7 | – | 162 | |||
| 6 | MR | 13 | 245 | 46/18/66 | 2.6 | – | 157 | |||
| >6 | IFN-α: NR | |||||||||
| 3/61/M‡ | ECTCL, NOS | T4N3B1 | 0 | 34 | 660 | 84/23/21 | 3.7 | 294 | ||
| 3 | PR | 39 | 452 | 70/24/35 | 2.9 | 200 | ||||
| 6 | MR | 32 | 300 | 47/27/44 | 1.7 | 256 | ||||
| >6 | IFN-γ: DP | |||||||||
| 4/69/M‡ | SS | T4N1B2 | 0 | 24 | 2359 | 86/1/9 | 86.0 | – | 193 | |
| 3 | NR | 38 | 2793 | 93/1/21 | 93.0 | – | 227 | |||
| 6 | MR | 30 | 2297 | 63/1/20 | 63.0 | – | 235 | |||
| 5/31/F‡ | SS | T4N3B2 | 0 | 50 | 653 | 82/8/32 | 10.3 | 717 | 214 | |
| 3 | NR | 52 | 835 | 84/7 | 12.0 | – | 203 | |||
| 6 | MR | 54 | 726 | 71/6/28 | 11.8 | 605 | 181 | |||
| >6 | IFN-α: PR | |||||||||
| 6/52/M‡ | SS | T4N3B2 | 0 | 50 | 1066 | 89/4/16 | 22.3 | 1556 | 203 | |
| 3 | NR | 39 | 2048 | 80/3/16 | 26.7 | 1523 | 224 | |||
| 6 | MR | 43 | 2839 | 89/3/12 | 29.7 | 5282 | 212 | |||
| >6 | IFN-α: PR | |||||||||
| 7/55/F | MF | T2NXB2 | 0 | 24 | 499 | 74/9/84 | 8.2 | – | 170 | |
| 3 | MR | 14 | 290 | 70/12/78 | 5.8 | – | 174 | |||
| 6 | PR | 22 | 537 | 69/8/80 | 8.6 | – | 197 | |||
| >6 | IFN-α: NR | |||||||||
| 8/54/F | SS | T4N3B2 | 0 | 31 | 695 | 86/4/62 | 21.5 | 627 | 263 | |
| 3 | PR | 25 | 374 | 83/3/51 | 27.7 | 524 | 260 | |||
| 6 | PR | 37 | 539 | 81/2/48 | 40.5 | 524 | 264 | |||
| >6 | IFN-α: NR | |||||||||
| 9/72/F | SS | T4N3B2 | 0 | 48 | 5576 | 98/0.5/5 | 196.0 | 10 919 | 336 | |
| 3 | MR | 43 | 5315 | 96/0.5/6 | 192.0 | 11 248 | 364 | |||
| 6 | MR | 41 | 5574 | 98/2/1 | 49.0 | 13 188 | 325 | |||
| >6 | IFN-α: NR | |||||||||
| 10/79/F | SS | T4N3B2 | 0 | 33 | 340 | 67/13/66 | 5.2 | – | 308 | |
| 3 | MR | 22 | 172 | 43/17/61 | 2.5 | – | 257 | |||
| 6 | NR | 24 | 133 | 56/8/57 | 7.0 | – | 241 | |||
| >6 | CR | |||||||||
| 11/77/M | ECTCL, NOS | T4N1B1 | 0 | 13 | 121 | 42/23/80 | 1.8 | – | 184 | |
| 3 | NR | 29 | 339 | 58/18/84 | 3.2 | – | 171 | |||
| 6 | MR | 15 | 171 | 59/20/83 | 3.0 | – | 191 | |||
| >6 | CR | |||||||||
| 12/72/F | SS | T4NXB2 | 0 | 0 | 0 | 73/5/35 | 14.6 | 899 | 212 | |
| 3 | PR | 0 | 0 | 69/5/33 | 13.8 | 776 | 194 | |||
| 6 | PR | 0 | 0 | 67/4/31 | 16.8 | 726 | 165 | |||
| >6 | CR |
TNBM, tumor-node-blood-visceral ratings at start of ECP (63); B rating as recommended by the ISCL (8). All cases were at M0.
The absolute number of CD4+CD7− cells for cases in which neoplastic cells have a reduced expression of CD7 estimated by subtracting absolute CD7 from absolute CD3 counts.
Patients 1–6 previously reported as cases 2, 16, 19, 21, 22, and 29, respectively (29).
DX, diagnosis; SS, Sézary syndrome; ECTCL, NOS, erythrodermic cutaneous T-cell lymphoma, not otherwise defined; MF, mycosis fungoides; IFN-α, interferon-α; CR, complete response; MR, minor response; NR, no response; SC, Sézary cells; LDH, lactate dehydrogenase; CD4P7M, CD4+CD7−, subset of T cells; PR, partial response; W, worse; DP, disease progression; M, male; F, female.